Jui-Lin Chen

Jui-Lin Chen

Auto-generated profile, based on publicly available information

Jui-Lin Chen

Vaccine Company, Inc., South San Francisco, California, 94080, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2020 in Nature Nanotechnology
Verified
Journal Article
Open access
PDF file
CFChelsea N. Fries
Chelsea N. Fries
ECElizabeth J. Curvino
Elizabeth J. Curvino
JCJui-Lin Chen
Jui-Lin Chen
SPSallie Permar
Sallie Permar
GFGenevieve G. Fouda
Genevieve G. Fouda
JCJoel H. Collier
Joel H. Collier
Despite the overwhelming success of vaccines in preventing infectious diseases, there remain numerous globally devastating diseases without fully protective vaccines, particularly human immunodeficiency virus (HIV), malaria and tuberculosis. Nanotechnology approaches are being developed both to design new vaccines against these diseases as well as to facilitate their global implementation. The reasons why a given pathogen may present difficulties for vaccine design are unique and tied to the co-evolutionary history of the pathogen and humans, but there are common challenges that nanotechnology is beginning to help address. In each case, a successful vaccine will need to raise immune responses that differ from the immune responses raised by normal infection. Nanomaterials, with their defined compositions, commonly modular construction, and length scales allowing the engagement of key immune pathways, collectively facilitate the iterative design process necessary to identify such protective immune responses and achieve them reliably. Nanomaterials also provide strategies for engineering the trafficking and delivery of vaccine components to key immune cells and lymphoid tissues, and they can be highly multivalent, improving their engagement with the immune system. This Review will discuss these aspects along with recent nanomaterial advances towards vaccines against infectious disease, with a particular emphasis on HIV/AIDS, malaria and tuberculosis.

23 September 2022 in Science Advances
Verified
Journal Article
Open access
JCJui-Lin Chen
Jui-Lin Chen
CFChelsea N. Fries
Chelsea N. Fries
SBStella J. Berendam
Stella J. Berendam
NRNicole S. Rodgers
Nicole S. Rodgers
EREmily F. Roe
Emily F. Roe
GFGenevieve G. Fouda
Genevieve G. Fouda
To develop vaccines for certain key global pathogens such as HIV, it is crucial to elicit both neutralizing and non-neutralizing Fc-mediated effector antibody functions. Clinical evidence indicates that non-neutralizing antibody functions including antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) contribute to protection against several pathogens. In this study, we demonstrated that conjugation of HIV Envelope (Env) antigen gp120 to a self-assembling nanofiber material named Q11 induced antibodies with higher breadth and functionality when compared to soluble gp120. Immunization with Q11-conjugated gp120 vaccine (gp120-Q11) demonstrated higher tier 1 neutralization, ADCP, and ADCC as compared to soluble gp120. Moreover, Q11 conjugation altered the Fc N-glycosylation profile of antigen-specific antibodies, leading to a phenotype associated with increased ADCC in animals immunized with gp120-Q11. Thus, this nanomaterial vaccine strategy can enhance non-neutralizing antibody functions possibly through modulation of immunoglobulin G Fc N-glycosylation.

1 May 2009 in Foodborne Pathogens and Disease
Verified
Journal Article
Closed access
JCJui-Lin Chen
Jui-Lin Chen
MCMing-Lun Chiang
Ming-Lun Chiang
CCCheng-Chun Chou
Cheng-Chun Chou
In the present study, the foodborne pathogen Bacillus cereus 1-4-1 was subjected to acid adaptation treatment by suspending the test organism in tryptic soy broth (pH 5.5) for 2 hours. The susceptibility of the acid-adapted and nonadapted cells of B. cereus 1-4-1 to high concentrations of ethanol (20%) and NaCl (20%) was then examined. In addition, the effect of acid adaptation on the protein expression profile of B. cereus 1-4-1 as well as the growth patterns of the acid-adapted and nonadapted cells of the test organism in the presence of various carbon and nitrogen sources were compared. Results revealed that acid-adapted B. cereus 1-4-1 was more susceptible to ethanol (20%) and NaCl (20%) than its nonadapted counterpart. Analysis with one-dimensional SDS-PAGE showed no distinct difference in the expression of the 16 proteins bands noted in the nonadapted cells compared with those of acid-adapted cells. Two-dimensional electrophoresis revealed that the acid adaptation treatment affected the expression of 26 species of protein, with the levels of 12 proteins increasing and 14 proteins decreasing in the cells of acid-adapted B. cereus 1-4-1 compared with those of the control cells. Furthermore, immunoblotting detected GroEL-like protein with a similar level in the acid-adapted and nonadapted cells of B. cereus 1-4-1 while failing to find the presence of a DnaK-like protein. B. cereus 1-4-1, regardless of acid adaptation, exhibited the highest maximum growth with sucrose as the carbon source while the maximum growth was found in the presence of either peptone, soytone, tryptone, or yeast extract as the nitrogen source, with these showing no significant difference. Finally, the growth patterns of the acid-adapted and nonadapted cells were similar.

1 July 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
APAbigail E. Powell
Abigail E. Powell
HCHannah Caruso
Hannah Caruso
SPSoyoon Park
Soyoon Park
JCJui-Lin Chen
Jui-Lin Chen
JOJessica O’REar
Jessica O’REar
BPBrad A. Palanski
Brad A. Palanski
Summary: Middle East respiratory syndrome coronavirus (MERS-CoV) was first identified as a human pathogen in 2012 and causes ongoing sporadic infections and outbreak clusters. Despite case fatality rates (CFRs) of over 30% and the pandemic potential associated with betacoronaviruses, a safe and efficacious vaccine has not been developed for prevention of MERS in at-risk individuals. Here we report the design, in vitro characterization, and preclinical evaluation of MERS-CoV antigens. Our lead candidate comprises a stabilized spike ectodomain displayed on a self-assembling ferritin nanoparticle that can be produced from a high-expressing, stable cell pool. This vaccine elicits robust antibody titers in BALB/c mice as measured by MERS- CoV pseudovirus and live-virus neutralization assays. Immunization of non-human primates (NHPs) with a single dose of Alhydrogel-adjuvanted vaccine elicits >10 3 geometric mean titer (GMT) of pseudovirus neutralizing antibodies that can be boosted with a second dose. These antibody levels are durable, with GMTs that surpass the post-prime levels for more than 5 months post-boost. Importantly, sera from these NHPs exhibit broad cross-reactivity against lentiviruses pseudotyped with spike proteins from MERS-CoV clades A, B, and C as well as a more distant pangolin merbecovirus. In transgenic mice expressing human DPP4, immunization provided dose-dependent protection against MERS-CoV lethal challenge, and in an established alpaca challenge model, immunization fully protected against MERS-CoV infection. This protein-based MERS-CoV nanoparticle vaccine is a promising candidate for advancement to clinical development to protect at-risk individuals and for future use in a potential outbreak setting.

19 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
RMRyan S. McCool
Ryan S. McCool
CACory M. Acreman
Cory M. Acreman
APAbigail E. Powell
Abigail E. Powell
SPSofia I. Picucci
Sofia I. Picucci
DSDaniel J. Stieh
Daniel J. Stieh
JMJason McLellan
Jason McLellan
Epstein-Barr virus (EBV), the causative agent of mononucleosis, is linked to over 140,000 annual cancer-related deaths globally and increases the risk of multiple sclerosis by up to 32-fold. As a herpesvirus, EBV establishes lifelong infection, and over 90% of U.S. adults are EBV-seropositive. Despite its significant disease burden, no approved EBV vaccines or therapeutics exist. Among EBV envelope glycoproteins, the fusion protein (gB) is strictly required for epithelial and B cell infection. Using a combination of AlphaFold-guided modeling, rational design, and ThermoMPNN-informed optimization, we engineered a stabilized prefusion gB variant, D2C3. This construct incorporates two inter-protomeric disulfide bonds and three cavity-filling substitutions, resulting in a melting temperature of 54 °C. Cryo-EM analysis of this construct allowed us to determine the prefusion structure of EBV gB, providing insights into the structural transitions required to adopt the postfusion conformation. Murine immunizations and depletion studies with human sera suggested a trend toward improved functional immunogenicity of D2C3 compared to postfusion gB. Collectively, these studies define engineering principles to stabilize class III fusion proteins, provide reagents to interrogate the human antibody response to EBV gB, and lay a foundation for further studies to develop EBV gB-based vaccine candidates.